Search Results

You are looking at 51 - 60 of 116 items for :

  • "novel therapy" x
  • All content x
Clear All
Full access

Vivian W.G. Burgers, Winette T.A. van der Graaf, Daniël J. van der Meer, Martin G. McCabe, Anita W. Rijneveld, Martin J. van den Bent, and Olga Husson

child or partner for a relatively long time, and a possible reversal of roles. 51 , 55 New Survivors New survivors can been characterized by patients receiving novel therapies, including immunotherapy or targeted therapy, which have significantly

Full access

Tanya M. Wildes, Derek L. Stirewalt, Bruno Medeiros, and Arti Hurria

(PFS)/time-to-progression (TTP), and overall survival (OS), 14 , 15 , 18 , 35 suggesting that auto-HCT may be a reasonable option for selected older adults with myeloma. The effectiveness of auto-HCT compared with conventional or novel therapies for

Full access

Rajmohan Murali, Deborah F. Delair, Sarah M. Bean, Nadeem R. Abu-Rustum, and Robert A. Soslow

role in the development and implementation of novel therapies targeting molecular/genomic alterations in endometrial cancer. Roles of pathology in the present era of precision oncology include identification of homogenous subsets of tumors, which are

Full access

Philip L. McCarthy

. Improved survival in multiple myeloma and the impact of novel therapies . Blood 2008 ; 111 : 2516 – 2520 . 2 Singhal S Mehta J Desikan R . Antitumor activity of thalidomide in refractory multiple myeloma . N Engl J Med 1999 ; 341 : 1565

Full access

Reshma Jagsi, Grace Huang, Kent Griffith, Brian J. Zikmund-Fisher, Nancy K. Janz, Jennifer J. Griggs, Steven J. Katz, and Sarah T. Hawley

-consistent treatment recommendations might relate to the expanded availability of clinical trial and novel therapies at cancer centers, and a possible greater willingness of experienced practitioners and experts in a field to deviate from guidelines or recognize that

Full access

Jeffrey A. Gilreath and George M. Rodgers

monoclonal antibodies used for solid tumors were associated with anemia. The category of targeted therapy now includes more than 40 agents. More studies are required to determine how targeted therapies will impact CAA. Novel Therapies Used to Treat

Full access

Suneel D. Kamath, Sheetal M. Kircher, and Al B. Benson III

influential through political advocacy to shape health policy, fund medical research, accelerate regulatory approval of novel therapies, and expand insurance coverage for specialized diagnostics, drugs, or devices. 1 – 3 According to the most recent Giving

Full access

Joseph Abi Jaoude, Ramez Kouzy, Walker Mainwaring, Timothy A. Lin, Austin B. Miller, Amit Jethanandani, Andres F. Espinoza, Dario Pasalic, Vivek Verma, Noam A. VanderWalde, Benjamin D. Smith, Grace L. Smith, C. David Fuller, Prajnan Das, Bruce D. Minsky, Claus Rödel, Emmanouil Fokas, Reshma Jagsi, Charles R. Thomas Jr, Ishwaria M. Subbiah, Cullen M. Taniguchi, and Ethan B. Ludmir

ensure patient safety and treatment tolerance. 19 However, recent data from patients receiving novel therapies, including immune checkpoint inhibitors, suggest similar toxicity profiles between patients with good and poor PS. 20 Moreover, the scoring of

Full access

Andrew W. Hahn, Smith Giri, Dilan Patel, Heather Sluder, Ari Vanderwalde, and Mike G. Martin

for novel therapies. Another promising therapeutic class for the treatment of metastatic UC is anti–programmed death-ligand 1 (PD-L1) antibodies. 27 Expression of PD-L1 enables cancer cells to elude immune surveillance and is thought to play a

Full access

Laura Spring, Rachel Greenup, Andrzej Niemierko, Lidia Schapira, Stephanie Haddad, Rachel Jimenez, Suzanne Coopey, Alphonse Taghian, Kevin S. Hughes, Steven J. Isakoff, Leif W. Ellisen, Barbara L. Smith, Michelle Specht, Beverly Moy, and Aditya Bardia

biomarkers, surrogate end points, and the efficacy of novel therapies. 11 Pathologic complete response (pCR) after NAC has been shown to be a surrogate marker for disease free-survival (DFS) and overall survival (OS), and, from a research perspective